Fighting Cancer Every Step of the Way™

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

Introducing the OraMark™ Laboratory Developed Test for the U.S!

Learn More about OraMark™
vb-homepage-image3

Dedicated to Early Intervention. And Life.™


Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The OncAlert™ Oral Cancer product line uses patented technology based on clinical science that shows possible presence of oral cancer in its earliest stages… even before visual or physical symptoms develop.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences™ products are based on patented technology that detects specific protein markers clinically shown to aid in the detection of early stage cancers, even prior to observation of visual or physical symptoms... more


Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more


Accurate and Objective Results at the Point-of-Care or in the Laboratory

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

MORE ABOUT VIGILANT'S ONCALERT™ TECHNOLOGY

News + Press

  • dentistryIQ

    Vigilant Biosciences announces three new OncAlert distribution agreements for Europe, Africa, and Latin America

    The new OncAlert agreements will further expand Vigilant Biosciences’ reach and support the company’s goal to deliver accurate and cost-effective tools to aid clinicians in the diagnosis and treatment of oral cancer. Vigilant Biosciences Inc., an innovator and developer of…more

  • vb-400x210

    Vigilant Biosciences Announces Three New Distribution Agreements for OncAlert™ Oral Cancer Product Line for Europe, Africa and Latin America

    FORT LAUDERDALE, Fla., – June 15, 2016 – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced three exclusive multi-year distribution agreements for sales and marketing…more

  • Nikon-s-Rob-Zibilich-Talks-to-Clinical-Lab-Products-on-the-Evolution-of-the-Clinical-Lab

    From the Editor: Liquefaction, Dx Style

    When technologies have matured to the point of market readiness, it can be hard to keep track of the many new products that suddenly become available to the marketplace. This spring, after many months of anticipation, early FDA approvals hint…more

  • logo_medscape_RGB300

    Oral Rinse Test Picks Up Early-Stage Oral Cancer

    An inexpensive oral rinse test has been shown to distinguish head and neck cancer patients from people who are at high risk for the disease, and offers hope that the diagnosis of oral cancer could be made at a much…more


©2011-2016 Vigilant Biosciences, Inc. All Rights Reserved.

×